Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS)

详细信息    查看全文

• 作者：Antonio Almeida^a ; ^{amalmeida@ipolisboa.min-saude.pt} ; Pierre Fenaux^b ; Alan F. List^c ; Azra Raza^d ; Uwe Platzbecker^e ; Valeria Santini^f
• 关键词：Myelodysplastic syndromes ; Non-del(5q) ; Anemia ; Red blood cell transfusion dependence ; Treatment
• 刊名：Leukemia Research
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：52
• 期：Complete
• 页码：50-57
• 全文大小：1293 K
• 卷排序：52

文摘

Primary goal of LR-MDS therapy is to reduce the impact of chronic RBC transfusions. Few treatment options are available after ESA failure. Recent insights have led to a better understanding of the disease heterogeneity. There is a need for a more individualized approach to therapy. Many new treatment options are being explored that may alter the course of the disease.